Shkreli Subpoenaed On Drug Prices, Refuses To Give Up Records
This article was originally published in Scrip
Executive Summary
Martin Shkreli, the former hedge-fund manager who recently lost his job as CEO at two drug companies after being arrested on fraud charges, has been subpoenaed by the House Oversight and Government Reform Committee to testify at a Jan. 26 hearing focused on the increases in the prices of older medicines – like the 5,000% spike in the cost for the toxoplasmosis drug Daraprim (pyrimethamine), which is sold by Turing Pharmaceuticals Inc., one of the firms he started and then was booted from.